Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Clin Pediatr (Phila) ; 62(12): 1489-1496, 2023 12.
Article in English | MEDLINE | ID: mdl-36964689

ABSTRACT

Infants can sustain traction injury to brachial plexus nerves during birth, called brachial plexus birth injury (BPBI). While spontaneous recovery is possible, upper extremity weakness can linger. We report our experience at a brachial plexus clinic from a retrospective chart review of infants with BPBI from September 2017 to September 2019. We determined Narakas Classification (NC) and Active Movement Scale (AMS) at predetermined follow-up points. Of 15 patients, 8 presented with NC-I, 5 with NC-II, and 2 with NC-III without Horner's syndrome. By 7 months, 3 had spontaneous recovery, and 4 achieved all and another 4 achieved most AMS5-7 scores. Eleven patients undergoing surgery had little-to-no improvement of shoulder abduction and shoulder external rotation AMS categories by 6 months. Our small sample size prevents us from making definitive conclusions but gave beneficial insight into our clinic barriers to follow-up, data collection, and collaboration with physical and occupational therapy.


Subject(s)
Birth Injuries , Brachial Plexus Neuropathies , Brachial Plexus , Infant , Humans , Brachial Plexus Neuropathies/diagnosis , Brachial Plexus Neuropathies/etiology , Brachial Plexus Neuropathies/surgery , Retrospective Studies , Brachial Plexus/injuries , Brachial Plexus/surgery , Range of Motion, Articular/physiology
2.
Am J Med Genet A ; 188(4): 1245-1250, 2022 04.
Article in English | MEDLINE | ID: mdl-34897952

ABSTRACT

The DST gene is located on chromosome 6p and encodes for a large protein. Alternative splicing of this protein produces the neuronal (a1-a3), muscular (b1-b3), and epithelial (e) isoforms. Hereditary sensory and autonomic neuropathy (HSAN) type VI is a rare autosomal recessive disorder due to mutations affecting the a2 isoform. We present a case of HSAN-VI in a male neonate born to consanguineous parents. Genome sequencing revealed a novel homozygous variant (DST_c.1118C > T; p.Pro373Leu) inherited from both parents. This case further expands the phenotype and genotype of this rare syndrome.


Subject(s)
Hereditary Sensory and Autonomic Neuropathies , Dystonin/genetics , Hereditary Sensory and Autonomic Neuropathies/diagnosis , Hereditary Sensory and Autonomic Neuropathies/genetics , Humans , Infant , Male , Neurons/metabolism , Phenotype , Protein Isoforms/genetics
3.
J Child Neurol ; 33(13): 817-819, 2018 11.
Article in English | MEDLINE | ID: mdl-30149783

ABSTRACT

A 13-year-old African American male presented with 2 months of subacute altered mental status, ptosis, areflexia, disordered gait, constipation, weight loss, abdominal and testicular pain, and hyperhidrosis. Initial workup at our facility was unrevealing until elevated serum mercury level was detected. Diagnosis of mercury toxicity was confirmed, and chelation therapy with succimer was started. After beginning succimer, the patient developed acute-onset weakness and was diagnosed with acute inflammatory demyelinating polyneuropathy. Supportive studies included elevated cerebrospinal fluid protein and acquired demyelinating polyneuropathy on nerve conduction study. He responded well to treatment with intravenous immunoglobulin and returned to his baseline state of health. Although there is a known association between mercury toxicity and axonal neuropathy, there is only 1 other case report of acute inflammatory demyelinating polyneuropathy in the setting of mercury toxicity. The nature of the correlation between these 2 entities in our case remains unclear.


Subject(s)
Guillain-Barre Syndrome/complications , Mercury Poisoning/complications , Adolescent , Electromyography , Evoked Potentials, Motor/physiology , Guillain-Barre Syndrome/diagnosis , Guillain-Barre Syndrome/drug therapy , Humans , Immunoglobulins, Intravenous/therapeutic use , Immunologic Factors/therapeutic use , Male , Mercury Poisoning/diagnosis , Mercury Poisoning/drug therapy , Neural Conduction/physiology
4.
J Clin Neuromuscul Dis ; 17(1): 13-7, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26301374

ABSTRACT

The classic phenotype of Friedreich ataxia is characterized by dysarthria, progressive limb and trunk ataxia, loss of reflexes, and gait disturbance with the onset of disease before the second decade. Homozygous trinucleotide repeat expansion of GAA in the FXN gene is found in 98% of patients. Two-5% of all patients have a repeat expansion on one allele and a point mutation on the other allele. Atypical phenotype is found in 25% of patients. A 10-year-old boy presented with congenital biliary atresia and progressive gait abnormality. His examination was significant for spastic gait, hyperreflexia, and sensory neuropathy. Genetic testing revealed a compound heterozygous mutation in the FXN gene. The absence of dysarthria and ataxia, retention of reflexes, absence of diabetes, and variable development of cardiomyopathy support a slow progression of disease with compound heterozygous mutation at G130V. Missense mutations are rare causes of Friedreich ataxia that can only be detected by sequencing of the FXN gene. Sequencing of the FXN gene is essential to make an early diagnosis when there is an atypical phenotype.


Subject(s)
Friedreich Ataxia/diagnosis , Friedreich Ataxia/physiopathology , Child , Electrodiagnosis , Friedreich Ataxia/genetics , Humans , Iron-Binding Proteins/genetics , Magnetic Resonance Imaging , Male , Neural Conduction/genetics , Trinucleotide Repeats/genetics , Frataxin
5.
Pediatr Neurol ; 52(5): 517-20, 2015 May.
Article in English | MEDLINE | ID: mdl-25882079

ABSTRACT

BACKGROUND: The direct charges for emergency department visits resulting from recurrent seizures are significant, and home intervention with abortive medications can be cost-saving. Over a 1-year period, we evaluated children with seizures who were seen in the emergency department, stabilized, and released. The information is necessary to assess the pharmacoeconomic advantages of at-home interventions for seizure emergencies. METHODS: We did a retrospective chart review of 90 patients and divided them into febrile versus nonfebrile seizures and existing versus new-onset seizure disorder. The hospital accounting department performed a charge analysis. RESULTS AND CONCLUSION: The total charges for all 90 patients treated for seizures in the emergency department were $219,945. The minimum was $370, for a patient with no history of febrile seizures. The maximum was $17,126, for a patient with a nonfebrile seizure and a history of seizures. This information allows a comparison with the cost of preventive medications, such as diazepam rectal gel or intranasal midazolam.


Subject(s)
Costs and Cost Analysis , Emergency Service, Hospital/economics , Seizures/economics , Emergency Service, Hospital/statistics & numerical data , Female , Humans , Male , Retrospective Studies , Seizures/epidemiology , Seizures/therapy
6.
J Child Neurol ; 29(4): 555-9, 2014 Apr.
Article in English | MEDLINE | ID: mdl-23481445

ABSTRACT

Baclofen is a γ-aminobutyric acid (GABA) agonist that is commonly prescribed for the treatment of spasticity in children. The clinical indications for baclofen use in the pediatric population have increased in recent years. Prescribing baclofen mandates education regarding abrupt withdrawal and overdose because of the severe clinical reactions this can precipitate. This report highlights the case of a patient who presented with acute onset of coma and a flaccid paralysis after baclofen overdose. We reviewed the presentation, clinical course, diagnostic studies, and outcome of this patient. A review of prior literature regarding baclofen overdose is included. Baclofen overdose is heralded by dose-related alteration in consciousness and weakness, progressing to coma and a flaccid paralysis. Screening for baclofen overdose is accomplished through high-power liquid chromatography. Baclofen overdose is treated with supportive care and antiepileptic medications as indicated. There is usually full spontaneous recovery with elimination of the medication.


Subject(s)
Baclofen/adverse effects , Coma/chemically induced , Drug Overdose/etiology , Muscle Relaxants, Central/adverse effects , Quadriplegia/chemically induced , Adolescent , Central Nervous System/pathology , Drug Overdose/complications , Epilepsy, Generalized/drug therapy , Female , Humans , Magnetic Resonance Imaging
7.
Toxicon ; 54(6): 779-83, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19520099

ABSTRACT

OBJECTIVE: Serious morbidity and mortality following snakebite injuries are common in tropical regions of the world. Although antivenom administration is clinically effective, it carries an important risk of early anaphylactic reactions, ranging from relatively benign nausea, vomiting, and urticaria to life-threatening angioedema, bronchospasm and hypotension. Currently, no adequately powered study has demonstrated significant benefit from the use of any prophylactic drug. A high rate of anaphylactic reactions observed during a trial of three different antivenoms in Ecuador prompted adoption of premedication with intravenous (i.v.) hydrocortisone and diphenhydramine together with dilution and slower administration of antivenom. DESIGN: In a rural mission hospital in Eastern Ecuador, 53 consecutive snakebite victims received a new antivenom regimen in 2004-2006, comprising prophylactic drugs and i.v. infusion of diluted antivenom over 60 min. They were compared to an historical control cohort of 76 patients treated in 1997-2002 without prophylactic drugs and with i.v. "push" injection of undiluted antivenom over 10 min. All these patients had incoagulable blood on admission and all were treated with Brazilian Instituto Butantan polyspecific antivenom. RESULTS: Baseline characteristics of the historical control and premedicated groups were broadly similar. In the historical group, early reaction rates were as follows: 51% of patients had no reaction; 35% had mild reactions; 6% moderate; and 6% severe. In the premedicated/slow i.v. group, 98% of patients had no reaction; 0 mild; 0 moderate; and 2% severe. The difference in reaction rates was statistically significant (p<0.001). CONCLUSIONS: Premedication with intravenous hydrocortisone and diphenhydramine together with dilution of antivenom and its administration by i.v. infusion over 60 min appeared to reduce both the frequency and severity of anaphylactic reactions. A randomized blinded controlled trial is needed to confirm these encouraging preliminary findings.


Subject(s)
Antivenins/toxicity , Adolescent , Adult , Antivenins/administration & dosage , Child , Drug Administration Routes , Ecuador , Female , Humans , Male
SELECTION OF CITATIONS
SEARCH DETAIL
...